help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. suppl_3, 16-20, May 2008; doi:10.1634/theoncologist.13-S3-16
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fandrey, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fandrey, J.

Erythropoietin Receptors on Tumor Cells: What Do They Mean?

Joachim Fandrey

Institut für Physiologie, Universität Duisburg-Essen, Essen, Germany

Key Words. Erythropoietin • Erythropoietin receptor • Erythropoietin receptor antibody • Heat shock protein (HSP) 70

Correspondence: Joachim Fandrey, M.D., Institut für Physiologie, Universität Duisburg-Essen, Hufelandstr. 55, D-45147 Essen, Germany. Telephone: 49-201-723-4600; Fax: 49-201-723-4648; e-mail: joachim.fandrey{at}uni-due.de

Disclosure: J.F. has received educational speaker honoraria and travel reimbursements from Janssen Pharmaceutica NV. No other potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article.

Given the apparent presence of erythropoietin receptors (EPORs) in cancer tissues, questions have been raised about the possible influence of erythropoiesis-stimulating agents (ESAs) on tumor growth and proliferation. Preclinical studies of ESAs have shown no greater tumor proliferation in cell lines and no adverse effect on treatment outcomes in animal models. Furthermore, it appears that the commercially available antibodies that have been used in clinical studies are not specific to EPORs. In particular, they detect isoforms of heat shock protein 70, which is found in tumor cells and is associated with poor prognosis. For this reason, results from clinical studies purporting to relate the administration of ESAs to shorter survival must be considered inconclusive and complicated by methodological and sampling issues. Ongoing studies will help clarify whether the existence of the EPOR has any relevance at all in the cancer setting.




This article has been cited by other articles:


Home page
 The OncologistHome page
M. S. Aapro
Editorial: Anemia Management with Erythropoiesis-Stimulating Agents: A Risk-Benefit Update
Oncologist, May 1, 2008; 13(suppl_3): 1 - 3.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.